Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Heart Failure with Reduced Ejection Fraction

Heart Failure with Reduced Ejection Fraction

Part of Heart Failure

16 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Heart Failure with Reduced Ejection Fraction

19 trials tracked for Heart Failure with Reduced Ejection Fraction: 6 in phase 3 or 4 and 4 with published results. The most-cited published study has 354 citations.

19Trials tracked
6Phase 3 & 4
0Recruiting
4With published results
Phase distribution
Phase 4 4 Phase 3 2 Phase 2 5 Phase 1 2 Other / NA 6
  1. Phase 4 Comparison of Pre- and Post-discharge Initiation of LCZ696 Therapy in HFrEF Patients After an Acute Decompensation Event Completed · 354 cited
  2. Phase 3 Study to Assess the Effect of Omecamtiv Mecarbil on Exercise Capacity in Subjects With Heart Failure Completed · 63 cited
  3. Phase 3 DETERMINE-reduced - Dapagliflozin Effect on Exercise Capacity Using a 6-minute Walk Test in Patients With Heart Failure With Reduced Ejection Fraction Completed · 60 cited
  4. Phase 4 Study to Assess Efficacy and Safety of SZC for the Management of High Potassium in Patients With Symptomatic HFrEF Receiving Spironolactone Completed · 55 cited
  5. Phase 4 The Effect of Vericiguat on Peripheral Vascular Function, Patient Health Status and Inflammation Completed
  6. Phase 4 HF Patients With LVADs Being Treated With SGLT2i Completed
Show 13 more trials
  1. Phase 2 Heart Failure Polypill at a Safety Net Hospital Completed
  2. Phase 2 v4 Study Evaluating the Safety, Tolerability and Preliminary Pharmacokinetics and Pharmacodynamics of MYK-491 Completed
  3. Phase 2 Developing Oral LT3 Therapy for Heart Failure - HFrEF Completed
  4. Phase 2 Safety and Tolerability of Initiating LCZ696 in Heart Failure Patients Completed
  5. Phase 2 Safety, PK, and Efficacy of Omecamtiv Mecarbil in Japanese Subjects With Heart Failure With Reduced Ejection Fraction Completed
  6. Phase 1 Study of JK07 in Subjects With Heart Failure With Reduced Ejection Fraction (HFrEF) Completed
  7. Phase 1 Ketone Pharmacokinetic Study in HFrEF Completed
  8. N/A Electronic Health Record-leveraged, Patient-centered, Intensification of Chronic Care for HF Completed
  9. N/A Building Electronic Tools To Enhance and Reinforce CArdiovascular REcommendations - Heart Failure (BETTER CARE-HF) Completed
  10. N/A Mid-Q Response Study Completed
  11. N/A Hemodynamic-GUIDEd Management of Heart Failure Completed
  12. N/A Pragmatic Trial of Messaging to Providers About Treatment of Heart Failure Completed
  13. N/A Dashboard Activated Services and Tele-Health for Heart Failure Completed

Showing the 19 most-cited and recently-updated of 19 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Heart Failure with Reduced Ejection Fraction: what the trials found

SGLT2 inhibitors were evaluated for their impact on cardiac dimensions, specifically showing no significant change in Left Ventricular End-diastolic Dimension (LVEDD) 1. In a separate study of dapagliflozin, patients showed a statistically significant improvement in the Kansas-City Cardiomyopathy Questionnaire-Total Symptom Score (KCCQ-TSS) at 16 weeks, though no significant changes were observed in physical limitation scores or 6-minute walk distance 7.

Regarding LCZ696, trials demonstrated that a significantly higher percentage of patients achieved and maintained either a 100 mg or 200 mg dose compared to the control group 3. Additionally, high numbers of participants successfully tolerated LCZ696 for at least two weeks across different RAAS strata 11.

Sodium zirconium cyclosilicate was shown to significantly increase the proportion of patients achieving a response defined by serum potassium levels between 3.5 and 5.0 mEq/L while on spironolactone (≥25 mg daily) compared to standard care 4. Omecamtiv Mecarbil resulted in a statistically significant decrease in total workload during cardiopulmonary exercise testing at week 20, though changes in peak oxygen uptake and ventilatory efficiency were not significant 6.

Vericiguat was also evaluated in an established phase 4 trial for this condition 5.

Recent results — preliminary, needs further review

  • * A heart failure polypill showed varying adherence ratios to individual components of GDMT (ranging from 71.1% to 83.7%) and resulted in blood pressure readings of 126 and 124 mmHg 2. * The CardioMEMS™ HF System did not show statistically significant differences in the composite outcome of heart failure hospitalizations, intravenous diuretic visits, and all-cause mortality 14. * A best practice alert for HFrEF notification and recommended therapies resulted in a higher percentage of patients with an increase in prescribed HFrEF therapy compared to standard care 15.

For the clinician treating this condition

  • SGLT2 inhibitors (specifically dapagliflozin) are associated with improved symptom scores (KCCQ-TSS), though they may not significantly impact 6-minute walk distance or physical limitation scores [1, 7].
  • Sodium zirconium cyclosilicate effectively improves the likelihood of patients maintaining spironolactone therapy while achieving target potassium levels 4.
  • LCZ696 shows high rates of dose achievement and tolerability across different RAAS strata [3, 11].

AI synthesis of 10 cited trials, updated Jun 28, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Observational study reveals 'tug-of-war' contraction patterns in healthy and infarcted hearts
Cardiology
Observational study reveals 'tug-of-war' contraction patterns in healthy and infarcted hearts New research reveals a hidden heart tug-of-war that causes failure
This observational study describes mesoscale contraction patterns in healthy individuals and patients with myocardial infarction.
A hidden tug-of-war inside your heart explains why some pumps fail while others keep going strong during stress.
medRxiv Apr 27, 2026
GLP-1 receptor agonists associated with lower mortality in HFrEF on GDMT
Cardiology RCT
GLP-1 receptor agonists associated with lower mortality in HFrEF on GDMT Heart Failure Patients Cut Death Risk With Common Diabetes Drug
In a retrospective, multicenter cohort study of 1,518 adults with HFrEF on guideline-directed therapy, GLP-1 receptor agonist use was associ…
Adding a common diabetes medication to standard heart failure treatment may significantly lower death rates.
medRxiv Apr 19, 2026
Qiliqiangxin capsule adjunctive therapy reduces cardiovascular death and hospitalization in patients with heart failure with reduced ejection fraction
Cardiology Meta-analysis
Qiliqiangxin capsule adjunctive therapy reduces cardiovascular death and hospitalization in patients with heart failure with reduced ejection fraction A Traditional Chinese Capsule Meets Modern Heart Failure Trials
This systematic review and meta-analysis evaluated Qiliqiangxin capsule as adjunctive therapy in 5,580 patients with heart failure with redu…
Adding a traditional Chinese medicine capsule to standard heart failure care reduced deaths and hospital stays in a review of 24 trials.
Apr 13, 2026
Remote monitoring chatbot increased GDMT target dose achievement in recently discharged HFrEF patients compared to standard care
Cardiology RCT
Remote monitoring chatbot increased GDMT target dose achievement in recently discharged HFrEF patients compared to standard care A Simple Chatbot After Heart Failure Hospitalization May Keep You Healthier and Out of the Hospital
This randomized controlled trial enrolled 66 patients with heart failure with reduced ejection fraction (HFrEF) recently discharged from the…
For people with heart failure, consistent digital check-ins after leaving the hospital could be the key to getting the right medication stre…
Apr 12, 2026

Research across Heart Failure

Related studies from across the Heart Failure family.

Prediction models for heart failure in type 2 diabetes show acceptable discrimination but lack prospective testing
Cardiology Meta-analysis
Prediction models for heart failure in type 2 diabetes show acceptable discrimination but lack prospective testing New Prediction Models Help Identify Heart Failure Risk in Diabetes
This meta-analysis of 65 studies evaluated prediction models for incident heart failure and heart failure hospitalization in people with typ…
New prediction models show promise in identifying heart failure risks for people living with type 2 diabetes.
Oct 29, 2026
Heart transplantation provides feasible treatment with favorable long-term survival for end-stage Chagas heart disease
Cardiology Meta-analysis
Heart transplantation provides feasible treatment with favorable long-term survival for end-stage Chagas heart disease Heart transplant offers long term survival for Chagas heart disease
This meta-analysis of 305 patients evaluates outcomes in Chagas heart disease transplant recipients. The analysis indicates that heart trans…
Heart transplants provide a viable path to long term survival for patients with advanced Chagas heart disease.
Frontiers Oct 28, 2026
Nursing-led strategies address patient, systemic, and socio-cultural barriers to cardiac rehabilitation participation
Cardiology Meta-analysis
Nursing-led strategies address patient, systemic, and socio-cultural barriers to cardiac rehabilitation participation Nurses help heart failure patients overcome barriers to cardiac rehab
This systematic review of 17 studies identifies nursing-led interventions as key facilitators for overcoming barriers to cardiac rehabilitat…
Many heart failure patients struggle to join rehab due to fear or travel issues, but nurse-led support can help them stay on track.
Frontiers Oct 27, 2026
Dapagliflozin associated with lower risk of heart failure in frail patients with aortic stenosis
Cardiology RCT
Dapagliflozin associated with lower risk of heart failure in frail patients with aortic stenosis Trial shows dapagliflozin may help frail patients with aortic stenosis
This post hoc analysis examined the impact of dapagliflozin on patients with severe aortic stenosis undergoing transcatheter aortic valve im…
A new analysis suggests the medication dapagliflozin may offer specific benefits for patients with aortic stenosis who are also experiencing…
Oct 24, 2026
Cardiac resynchronization therapy increases left ventricular ejection fraction by 9.95% in cancer-related heart failure
Oncology Meta-analysis
Cardiac resynchronization therapy increases left ventricular ejection fraction by 9.95% in cancer-related heart failure Heart therapy shows promise for cancer patients with heart damage
This meta-analysis of 110 patients with cancer therapy-related cardiac dysfunction found that cardiac resynchronization therapy (CRT) increa…
A new look at heart treatments shows that a specific device can improve heart function for cancer survivors with heart damage.
Oct 23, 2026
Individualized mechanical circulatory support is necessary as increased hemodynamic support does not uniformly improve survival
Cardiology Sys. Review
Individualized mechanical circulatory support is necessary as increased hemodynamic support does not uniformly improve survival Mechanical Support for Cardiogenic Shock Does Not Uniformly Improve Survival
This mini review examines the role of short-term mechanical circulatory support (MCS) in patients with cardiogenic shock, including those wi…
Newer reviews suggest that while mechanical support helps heart function, it does not always lead to better survival rates for patients in c…
Frontiers Oct 22, 2026
Qili Qiangxin plus conventional medicine improves surrogate markers in heart failure after myocardial infarction
Drug Pipeline Meta-analysis
Qili Qiangxin plus conventional medicine improves surrogate markers in heart failure after myocardial infarction Qili Qiangxin May Improve Heart Function After Heart Attack
This meta-analysis of 1391 patients found that Qili Qiangxin combined with conventional Western medicine led to greater reductions in NT-pro…
Adding Qili Qiangxin to standard medicine may improve heart function and quality of life for patients following a heart attack.
Frontiers Oct 20, 2026
RAAS inhibitors modulate inflammatory responses and oxidative stress across multiple chronic conditions
Drug Pipeline Sys. Review
RAAS inhibitors modulate inflammatory responses and oxidative stress across multiple chronic conditions RAAS Inhibitors May Protect Organs Beyond Lowering Blood Pressure
This systematic review synthesizes the roles of ACEI, ARB, DRI, ARNI, and MRA in modulating inflammatory responses and oxidative stress. The…
New research suggests certain blood pressure medications may protect the heart, kidneys, and lungs by reducing inflammation and oxidative st…
Frontiers Oct 16, 2026
An RV-first framework addresses controversies in tricuspid intervention and right ventricular support for cardiogenic shock
Cardiology Sys. Review
An RV-first framework addresses controversies in tricuspid intervention and right ventricular support for cardiogenic shock New framework aims to improve care for heart failure patients
This narrative review explores the role of transcatheter tricuspid interventions and mechanical circulatory support for patients with advanc…
Doctors are looking for better ways to treat heart failure and cardiogenic shock using a new approach to manage the right side of the heart.
Frontiers Oct 15, 2026
SGLT-2is and GLP-1RAs significantly reduce heart failure related composite endpoints in type 2 diabetes
Diabetes & Endocrinology Meta-analysis
SGLT-2is and GLP-1RAs significantly reduce heart failure related composite endpoints in type 2 diabetes SGLT2 inhibitors and GLP-1RAs both improve heart failure outcomes
This network meta-analysis of 13,886 patients with type 2 diabetes and heart failure found that both SGLT-2is and GLP-1RAs significantly red…
New data shows both SGLT2 inhibitors and GLP-1RAs effectively reduce heart failure risks for people with type 2 diabetes.
Frontiers Oct 14, 2026
Ventricular Arterial Coupling Surrogates Predict Mortality and Adverse Events in Acute Heart Failure
Cardiology Meta-analysis
Ventricular Arterial Coupling Surrogates Predict Mortality and Adverse Events in Acute Heart Failure Ventricular-arterial coupling measures help identify high risk in heart failure
Meta-analysis of 36,989 patients reveals that RV-PA uncoupling predicts mortality while LV-Ao uncoupling identifies risk for in-hospital car…
New data shows that specific heart measurements can help doctors identify which heart failure patients face the highest risk of death or com…
Oct 7, 2026
Longer heart failure duration correlates with lower LV strain and higher HF event risk
Cardiology RCT
Longer heart failure duration correlates with lower LV strain and higher HF event risk Longer Heart Failure Duration Tied to Worse Heart Structure and Function
This randomized controlled trial of 626 patients with heart failure with preserved ejection fraction (HFpEF) found that longer diagnosis dur…
In a 626-patient study, people who had heart failure longer showed weaker heart pumping and higher risk of worsening symptoms.
Oct 7, 2026

Questions about Heart Failure with Reduced Ejection Fraction

Does adding qiliqiangxin to my current treatment help my heart failure with reduced ejection fraction?

Yes, adding qiliqiangxin to your current treatment may reduce cardiovascular death and heart failure hospitalization in HFrEF, based on a large trial and meta-analysis.

Full answer →
Will taking Cimlanod cause low blood pressure in patients with heart failure with reduced ejection fraction?

Yes, Cimlanod significantly increases the risk of low blood pressure (hypotension) in patients with heart failure with reduced ejection fraction, according to a meta-analysis.

Full answer →
Does Cimlanod lower the chance of dying from heart failure with reduced ejection fraction?

No, Cimlanod does not significantly lower the chance of dying from heart failure with reduced ejection fraction based on current evidence.

Full answer →